Patient preferences for treatment pathways in early-stage breast cancer: application of a discrete choice experiment
Discussions with patients should be personalized per individual preferences and should cover the entire treatment pathway, not just the initial treatment step.
Authors
- Oliver Will (ORCID: https://orcid.org/0000-0002-6514-8298)
- Chikako Shimizu (ORCID: https://orcid.org/0000-0003-1448-5865)
- Christian Jackisch (ORCID: https://orcid.org/0000-0001-8537-3743)
- Kathleen Marie Beusterien (ORCID: https://orcid.org/0000-0001-7786-5422)
- Emuella Flood (ORCID: https://orcid.org/0000-0002-3526-9670)
- Xavier Guillaume (ORCID: https://orcid.org/0000-0002-9255-1680)
- Susan McCutcheon
- Stella Mokiou (ORCID: https://orcid.org/0009-0003-9914-0213)
- Emily Mulvihill (ORCID: https://orcid.org/0000-0002-1430-8837)
Institutions
- AstraZeneca (United Kingdom) (GB)
- Oracle (United States) (US)
- National Center for Global Health and Medicine (JP)
- AstraZeneca (Brazil) (BR)
- Center for Global Health (US)
- Kliniken Essen-Mitte (DE)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1080/14796694.2025.2517000
- Citations
- 1
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- AstraZeneca